GRP-R-based pharmaceuticals and specific radioactive, cytotoxic, and nonradioactive GRP-analogs have been designed and tested in various animal tumor models with the aim of receptor targeting for tumor diagnosis or anti-cancer therapy [20, 37–41]. The gene discussed is GRPR; the disease is cancer.